ABSTRACT We present a case of a 66-year-old male patient with primary angle closure glaucoma who underwent cataract surgery. He was also under tamsulosin treatment for benign prostate hyperplasia. Due to high intraocular pressure and shallow anterior chamber, 150 mL of 20% mannitol was given intravenously, before phacoemulcification cataract surgery. The iris prolapsed from the main incision and the pupil constricted, right after the main incision was opened and the pupil shrank. An additional 150 mL of 20% mannitol was […]

ABSTRACT Objective: To evaluate the impact of selective laser trabeculoplasty (SLT) on resource savings and medication costs. Methods: Retrospective study of patients with open-angle glaucoma (OAG) who underwent SLT as a replacement therapy for eye drops and were followed for up to 1 year. The ability to reduce intraocular pressure (IOP) and the amount of eye drops were evaluated, as well as the monthly cost of medications during the follow-up. The annual cost of medications was also calculated. The results […]

ABSTRACT Objective: To evaluate 1-year real-world results of effectiveness and safety of selective laser trabeculoplasty as an alternative to eye drops in patients with early to moderate open-angle glaucoma. Methods: This is a retrospective longitudinal study of a series of cases undergoing selective laser trabeculoplasty in patients with early to moderate open-angle glaucoma who were in use of topical anti-glaucoma therapy. The ability to reduce the intraocular pressure and the medication burden were evaluated, as well as the occurrence of […]

ABSTRACT Objective To evaluate the preliminary medium-term results (up to 6 months) of the stand-alone use of XEN® Gel Stent implantation or in combination with cataract surgery in the Brazilian population. Methods A retrospective longitudinal study was carried out on eyes with primary open-angle glaucoma consecutively submitted to XEN® Gel Stent implantation surgery alone (XEN® Group) or in combination with cataract surgery (Phaco-XEN® Group) in the same center between April and December 2023. The ability to reduce intraocular pressure and […]

ABSTRACT Objective: To evaluate the economic impact of starting the treatment of primary open angle glaucoma with non-pharmacological strategies within the scope of reference centers for the treatment of glaucoma in the Unified Health System. Methods: The population of this study comes from a hypothetical cohort of patients aged 60 years with initial primary open angle glaucoma. The reference strategy (strategy 1) is based only on the use of eye drops, following the guidelines of the clinical protocol of the […]

ABSTRACT Objective: To evaluate structural and visual field (VF) changes after ≥1 year of a single acute primary angle closure (APAC) attack using spectral-domain optical coherence tomography (SD-OCT) and standard automated perimetry (SAP). Methods: Patients with a single unilateral APAC crisis at least 1 year ago were included consecutively from 2013 to 2016. Contralateral eye was used as control. All patients underwent ophthalmic examination, RNFL imaging by SD-OCT, and SAP using Octopus 1-2-3. Results: 54 eyes (27 patients) were enrolled. […]

ABSTRACT Glaucoma is considered the biggest cause of irreversible blindness in the world and the increase in intraocular pressure is its main risk factor. Usually, the initial therapy for glaucoma consists of reducing IOP through the instillation of topical hypotensive drugs, with antiglaucoma surgeries being normally reserved for cases in which disease control is not clinically achieved. Classically, the surgical treatment of glaucoma is performed using filtering procedures: trabeculectomy; non-penetrating sclerotomy and glaucoma drainage devices. The acronym MIGS (Minimally Invasive […]

ABSTRACT Purpose To evaluate the cost-utility of the iStent inject® for the treatment of mild-to-moderate open-angle glaucoma (OAG) within the Brazilian Unified Health System (SUS). Methods A Markov model was developed, in which the effectiveness outcome measure was the incremental cost-effectiveness ratio (ICER: R$ / QALY quality-adjusted life-year). Direct medical costs were obtained from the SUS perspective. The base case comprised of a hypothetical cohort of patients with OAG using topical medication and being managed according to the Clinical Protocol […]